Physician profile
William A Price
NPI 1710953674
$1,679.04
in general payments reported to CMS, 2019-2025
18 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.57 · 2020: $65.51 · 2021: $191 · 2022: $429 · 2023: $254 · 2024: $321 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.16 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.29 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $343.82 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.01 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $137.60 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $131.79 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $96.92 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $62.17 | 2021-2023 | Aristada, Vivitrol, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $49.36 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $46.09 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $44.69 | 2021-2025 | Ingrezza |
| Noven Therapeutics, LLC | $39.94 | 2022 | |
| Lundbeck LLC | $34.62 | 2021-2023 | Rexulti |
| Axsome Therapeutics, INC. | $29.75 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $23.12 | 2025 | Fanapt, Hetlioz |
| Noven Pharmaceuticals, INC. | $18.47 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $16.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.19 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.